Drugs / LMB-9 immunotoxin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00005858 | Apr 2000 → Dec 2003 | breast cancer, colorectal cancer, lung cancer, malignant pancreatic neoplasm +2 | University of Maryland, Baltimore | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMB-9 immunotoxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005858 ↗ |
| Action | Deplete | “The LMB-9 immunotoxin can locate tumor cells and kill them without harming normal cells.” NCT00005858 ↗ |
| Modality | Protein / enzyme biologic | “a Recombinant Disulfide Stabilized Anti-Lewis Y Immunotoxin” NCT00005858 ↗ |
| Route | Intravenous | “Patients receive LMB-9 immunotoxin IV continuously for 10 days.” NCT00005858 ↗ |